

Index

A

Androgen receptor (AR), 190, 193, 228, 229, 234, 236

B

Breast cancer cells, 62, 63, 66, 70, 72, 76, 89, 99, 104, 105, 114, 117, 120–122, 193–197, 202, 204, 208–210, 212

C

Cell

adhesion, 99, 103, 107, 114, 122, 172, 196, 271
cytokines, 9, 10, 18, 83, 98, 117–121, 168, 172, 182, 192, 205, 207, 210, 236, 245, 248–257, 273, 274

F

Filamin A, 98, 102, 106, 110–114, 121, 123

I

Inflammation, 9, 83, 205, 234, 245, 248, 251–256
Integrin, 99, 114, 119, 196, 197
Invasion, 86, 87, 99, 104, 107, 109, 113, 119–121, 123, 168, 194, 196, 197, 212, 266, 267, 269

J

Janus-kinase 2 (JAK2), 98, 226, 235, 271, 272

L

Lactotrope, 39, 42, 51

M

Matrix metalloproteases (MMPs), 119–121, 271
Mitogen-activated protein kinase (MAPK), 5, 21, 44–46, 48, 52, 103, 222, 252, 266, 271
motility, 43, 97–99, 103, 106–109, 112–115, 117, 123
Myeloid cells, 251, 253, 254, 256, 257

P

p21-activated kinase 1 (PAK1), 98, 99, 116, 120, 122
 β pix, 111, 116, 117, 122
Phosphatidylinositol-3-Kinase (PI3K), 8, 18, 24, 45, 48, 52, 98, 181, 235, 266
Pituitary gland, 37–42, 47, 62, 85, 86, 140, 235, 243, 245, 247, 270
Prolactin receptor (PRL-R), 43, 98, 168
Prolactin-induced protein (PIP), 189–197
Prolactinoma, 2, 38, 44–52, 86

S

Signaling, 39, 42, 180, 195, 196, 274
CK2, 47
Hippo, 47
MAPK, 44, 45
PI3K, 45, 46
PRL/STAT5, 226, 227
TGF β , 46, 47

T

Tumorigenesis, 4, 7, 11, 42, 46, 50, 52, 64, 74, 202, 224